Key result
Catheter ablation for post-transplant atrial flutter nearly doubles median survival over medical management alone.
Why the study?
Orthotopic heart transplantation creates a unique electrophysiologic substrate that alters mechanisms and management of atrial tachyarrhythmias, necessitating synthesis of current evidence on catheter ablation.
Does catheter ablation improve survival and rhythm control in orthotopic heart transplant recipients with atrial arrhythmias compared to medical management alone?
Does catheter ablation improve survival and rhythm control in orthotopic heart transplant recipients with atrial arrhythmias compared to medical management alone?
Catheter ablation is highly effective for treating atrial flutter in heart transplant recipients and provides a significant survival advantage over medical management alone.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ablation survival benefit in transplant flutter; leaves open randomized validation before adoption.
Orthotopic heart transplantation (OHT) creates a surgically altered electrophysiologic substrate defined by the suture-line scar, residual recipient atrial tissue, and autonomic denervation, which fundamentally alters the mechanisms, presentation, and management of atrial tachyarrhythmias. This narrative review synthesizes current evidence on the mechanisms, mapping strategies, procedural safety considerations, and outcomes of catheter ablation (CA) for atrial arrhythmias after OHT, on the basis of a structured search of PubMed and Embase (1995-2025). Atrial flutter, particularly cavotricuspid isthmus-dependent macroreentry, is the dominant arrhythmia in stable orthotopic heart transplant recipients. The ablation isthmus is anatomically redefined by suture lines rather than by the native inferior vena cava, and CA achieves acute success rates exceeding 90% for cavotricuspid isthmus-dependent flutter, with a significant survival benefit over medical management alone (median = 11.3 vs 5.8 years; P = .026). Atrial fibrillation is uncommon in stable recipients and, when present, most often arises from residual recipient atrial tissue or donor-recipient conduction bridges; ablation requires individualized electroanatomic mapping rather than routine pulmonary vein isolation. Atrioatrial conduction develops in approximately 20%-30% of patients presenting with arrhythmias, with a mean onset of 10.1 years after transplantation. Procedural considerations unique to OHT include protamine hypersensitivity risk, rhythm misclassification due to dual atrial physiology, anticoagulation complexity, and drug-immunosuppressant interactions, which collectively strengthen the rationale for ablation over pharmacologic therapy. CA is feasible, effective, and associated with improved survival in appropriately selected orthotopic heart transplant recipients. Prospective multicenter registries with standardized reporting are needed to advance evidence-based practice in this population.
No takes yet. Share an insight, caveat, or question.
Sukhon et al. (2026) conducted a review in Atrial arrhythmias after orthotopic heart transplantation. Catheter ablation vs. Medical management alone was evaluated on Survival (median years) (p=.026). Catheter ablation for cavotricuspid isthmus-dependent flutter in orthotopic heart transplant recipients provided a significant survival benefit over medical management alone (median 11.3 vs 5.8 years; P=0.026).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: